Butterfly Network, Inc. is a medical technology company that develops semiconductor-based point-of-care ultrasound devices and software. The company’s core business centers on the Ultrasound-on-Chip platform, which powers portable, single-probe imaging devices that connect to cloud-based software for real-time data access. Key products include the Butterfly iQ3, iQ+, and iQ probes, along with the Compass AI software suite for health system integration and the Butterfly Embedded licensing program for non-medical applications. The company serves healthcare systems, individual physicians, and educational institutions globally, with additional deployments in low-resource settings through global health partnerships. Butterfly also offers veterinary imaging solutions and an ecosystem for third-party AI developers via the Butterfly Garden platform. Founded in 2011, the company completed a business combination with Longview Acquisition Corp. in 2021.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage butterflynetwork.com
Sector Healthcare IR page ir.butterflynetwork.com/overview/default.aspx
Tags
point-of-care ultrasound, semiconductor ultrasound, portable imaging, medical software, veterinary imaging, ai diagnostics, cloud connectivity, healthcare education, Butterfly iQ3, Butterfly iQ+, Butterfly iQ, Compass AI, Butterfly Embedded, Butterfly Garden, Ultrasound-on-Chip, Longview Acquisition Corp.
Press page —

Metrics

Valuation  
Market cap $ 1.652B
Market cap (USD) $ 1.652B
P/E -29.52
PEG —
P/BV 8.96
P/S 13.40
P/OCF -70.60
P/FCF -59.96
Dividend yield —
Turnover / mcap —
Returns  
ROE -42.2%
ROI -121.9%
ROIC -102.5%
Profit margin -79.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 55
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 97.61M 82.056M 65.9M 73.39M 62.565M —
Net profit -77.064M -72.492M -133.7M -168.723M -32.409M -3.455M
Free cash flow -16.048M -44.401M -104.603M -187.417M -197.064M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.8 3.12 1.08 2.46 6.69 11.17
Price performance 12m 0.22 1.89 -0.56 -0.63 -0.4 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 5.75M 11.9M 14.7M 13.4M 20.8M 26.7M
↳ YoY growth +107.5% +23.0% -8.6% +55.0% +28.6%
↳ 5y CAGR +36.0%
Lease liabilities (USD) — — — 29.1M 31.9M 25M 22.8M 20.4M
Cash and deposits (USD) 215M 90M 158,599 423M 163M 134M 88.8M 150M
Intangible assets (USD) — — — — — 10.3M 8.92M 7.52M
Right-of-use assets (USD) — — — 24.1M 21.6M 15.7M 14.2M 12.7M
Cash flow detail
Operating cash flow (USD) — -120M -1.17M -189M -169M -98.8M -41.7M -12.7M
Purchases of property, plant and equipment (USD) — -4.47M -2.38M -7.88M -18.3M -5.78M -2.69M -3.35M
Change in receivables (cash effect) (USD) — -1.2M -4.38M -6.13M -3.06M -162,000 -8.5M -6.75M
Change in inventories (cash effect) (USD) — -1.39M -23.5M -11.3M -24.5M -34.1M 2.22M 1.43M
Change in payables (cash effect) (USD) — — 2.79M — — — — —
Interest paid (cash effect) (USD) — — — — — 0.00 -190,000 -810,000
Income taxes paid (cash effect) (USD) — — -22,000 — — -99,000 -99,000 -101,000
Share-based compensation (USD) — 6.04M 11M 47.8M 42.5M 27.5M 21M 23.4M
Operating cash flow before change in receivables (USD) — -119M -77.3M -183M -166M -98.7M -33.2M -5.95M
Free cash flow (OCF - PPE - intangibles) (USD) — -125M -84.1M -197M -187M -105M -44.4M -16M
Income detail
Research and development expense (USD) — 48.9M 49.7M 74.5M 89.1M 55.6M 37.8M 36.3M
↳ 5y CAGR -5.0% -6.1%
Total comprehensive income (USD) — — — — — -134M -72.5M -77.1M
Comprehensive income to owners (USD) — — — — — -134M -72.5M -77.1M
Provision for credit losses (USD) — — 576,000 -54,000 -315,000 -1.45M -1.13M -993,000
Credit cost ratio (credit losses / average receivables) (%) — — — 0.6% 2.4% 10.3% 6.6% 4.2%
Reported Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Mar 23, 2023 Feb 27, 2026 Feb 27, 2026 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

10/29/2026

Beats High End of Quarterly Revenue and Adjusted EBITDA Guidance

  • Delivered quarterly Revenue of $32.6 million, driven in part by Embedded revenue
  • Recorded highest gross margin in Company history at 73%
  • Management increases Full Year Revenue and Adjusted EBITDA Guidance

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)-- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “Our third quarter results came in ahead of guidance on both revenue and adjusted EBITDA, and we posted the highest gross margin in Butterfly’s history. We saw strength across our business. The enterprise pipeline is turning into signed deals, and achieving FedRAMP authorization puts larger federal opportunities on the table. Home & Community Care has also moved from building the program to executing it, with first revenue expected this November.”

DeVivo continued, “What excites me most is that our progress is compounding as we laid out. Our Ultrasound-on-Chip™ platform is taking Butterfly into entirely new categories, from brain-computer interfaces to physical AI. The first Embedded partner product is now on the market, and we have next-generation technology in motion. Every step forward expands the markets we can serve, and more than a decade of investment in this semiconductor platform is beginning to deliver on the vast potential we have expected.”

Recent Operational and Strategic Highlights:

  • Butterfly Embedded™: Added three BCI partners, including the announcements of Merge Labs and Bridge Neurotech in the third quarter, while Mendaera became the first partner to launch a commercial product built on Butterfly technology on October 1, 2026.

  • Compass AI™ and Enterprise Momentum: Closed five 7-figure and ten 6-figure TCV enterprise deals in the quarter.

  • FedRAMP: Officially achieved FedRAMP authorization as expected, supporting federal and VA pipeline opportunities.

  • Medical Education:Announced the Lighthouse program with VCOM, a multi-year partnership to equip every VCOM student with a Butterfly device and generate insights on POCUS use from medical school into residency.

  • Butterfly Garden™: Signed five new partners, and DeepEcho became the first international and first maternal health partner application to go live on October 23, 2026 .

  • Home & Community Care: Entered the implementation phase to launch the first state, with scanning set to begin in November and initial revenue expected in the fourth quarter.

  • International Expansion: Built momentum in Brazil, and added a new distribution partner in Taiwan.

  • Innovation Roadmap: Advanced development of the Apollo chip on schedule; prepared a limited release of wearable research devices for Embedded partners; and continue preparations to launch a next-generation product powered by the P5.1 chip in early 2027.

Three Months Ended September 30, 2026 Financial Results

Revenue: Total revenue was $32.6 million, representing growth of 52% from $21.5 million in the third quarter of 2025. U.S. revenue was $27.5 million, up 71% from prior year, primarily driven by revenue from our various Butterfly Embedded™ partnerships, including our co-development partnership with Midjourney, as well as increased probe sales volume to our health system, distributor, and eCommerce customers. International revenue decreased 5% year-over-year to $5.1 million, largely resulting from decreased probe sales to our global health partners.

Gross margin: Gross profit was $23.8 million versus a gross loss of $3.8 million in the prior year period, and adjusted gross profit was $23.8 million versus $13.7 million in the prior year period. Total gross margin, on a GAAP basis, was 73.0% compared to (17.5)% in the prior year period, and adjusted gross margin increased to 73.0% from 63.9% in the prior year period. The $27.6 million increase in GAAP gross margin is due in part to the $17.4 million write-down of excess and obsolete inventory that was recognized during the prior year period, which is excluded from adjusted gross profit and adjusted gross margin. The remainder of the increase in GAAP gross margin, as well as the $10.1 million increase in adjusted gross margin, was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as our increased probe sales volume in the current year.

Operating expenses: Operating expenses were $37.4 million, up 19% from $31.4 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.6 million, compared to $23.7 million in the third quarter of 2025, largely reflecting increased headcount in the current year from investments we’ve made in our internal capabilities throughout the past 12 months to support revenue growth as well as our product and software development projects.

Net loss: Net loss was $12.8 million, compared to $34.0 million in the prior year period.

Adjusted EBITDA: Adjusted EBITDA loss was $1.2 million, an improvement of 85% compared to $8.1 million in the prior year period.

EPS: EPS was $(0.05), compared to $(0.13) in the prior year period.

Adjusted EPS: Adjusted EPS was $(0.01), compared to $(0.04) in the prior year period.

Cash and cash equivalents: Cash and cash equivalents were $122.3 million as of September 30, 2026.

Guidance

Raised revenue guidance and adjusted EBITDA guidance for the Fiscal Year 2026:

  • Revenue of $123 million to $126 million, or approximately 26% to 29% growth
  • Adjusted EBITDA loss of $12 million to $15 million

Provided revenue guidance and adjusted EBITDA guidance for the 4th Quarter of 2026:

  • Revenue of $31 million to $34 million, or approximately 3% growth year-over-year at the midpoint
  • Adjusted EBITDA loss of $3 million to $6 million

Reconciliation of GAAP to Adjusted

Reconciliations of gross profit and gross margin to adjusted gross profit and adjusted gross margin and of net loss and EPS to adjusted net loss, adjusted EBITDA, and adjusted EPS for the three and nine months ended September 30, 2026, and 2025 are provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”

Conference Call

A conference call and webcast to discuss third quarter 2026 financial performance and operational progress is scheduled for 8:00 am ET on October 29, 2026. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at ir.butterflynetwork.com/events-and-presentations . Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:

US Toll Free: +1 833-461-5787
US East Local: +1 585-542-9983
US West Local: +1 626-884-3620
CA Local: +1 365-657-4084
UK Local: +44 117 389 0104
UK Toll Free: +44 808 196 8935
All dial-in numbers: https://help.events.q4inc.com/eahc/international-dial-in-numbers

Meeting ID: 731 501 731

After the live webcast, the call will be archived on Butterfly’s Investor Relations events page. In addition, a telephone replay of the call will be available until November 5, 2026, by dialing:

Toll Free: +1 833-309-1852
Meeting ID: 731 501 731

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is driving a digital revolution in ultrasound imaging and sensing with its proprietary Ultrasound-on-Chip™ semiconductor technology and software solutions. Butterfly first proved its technology in the point-of-care ultrasound market – commercializing the world’s first single-probe, whole-body portable ultrasound device, which is now on its best-selling, third-generation: Butterfly iQ3™. The Company combines its advanced hardware with cloud software and AI, an enterprise workflow solution (Compass AI™) and other offerings to drive adoption of affordable, accessible ultrasound. Butterfly also enables third-party development of imaging AI apps through Butterfly Garden™, its software development kit and AI marketplace.

In addition to its medical imaging products, Butterfly Embedded™ is the Company’s Ultrasound-on-Chip™ licensing and co-development business designed to enable a new wave of ultrasound-enabled technologies across non-competitive healthcare markets and beyond. Through Butterfly Embedded™, partners can build and scale novel ultrasound applications powered by Butterfly’s proprietary semiconductor chip and software platform.

Butterfly’s innovations have been recognized by Prix Galien USA, Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements. To learn more, visit: www.butterflynetwork.com .

Non-GAAP Financial Measures

In addition to providing financial measures based on generally accepted accounting principles in the United States of America (“GAAP”), we provide additional financial measures that are not prepared in accordance with GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are adjusted gross profit, adjusted gross margin, adjusted net loss, adjusted EBITDA, and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.

The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross profit, adjusted gross margin, adjusted net loss, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit, gross margin, net loss, and EPS.

The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of gross profit and gross margin to adjusted gross profit and adjusted gross margin and of net loss and EPS to adjusted net loss, adjusted EBITDA, and adjusted EPS, the most directly comparable GAAP financial measures. Reconciliations of our non-GAAP financial measures to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results and guidance, including revenue and adjusted EBITDA expectations for the fourth quarter and full year 2026, revenue growth, future performance of our ultrasound business and Embedded opportunities (inclusive of co-development, revenue share/commercialization revenue, chip purchases, and/or chip licensing opportunities through the Embedded program); the timing, scope, and revenue potential of our Butterfly Home and Community Care business, including expectations regarding the commercial launch of our first state program and the timing of initial revenue; expectations regarding the achievement of FedRAMP certification and the expansion of sales to government agencies, including the U.S. Department of Veterans Affairs; the expansion of our Compass AI enterprise software pipeline and related revenue opportunities; expectations regarding international market expansion, including opportunities in Brazil and Taiwan; development and commercialization of products and services, and the size and potential growth of current or future markets for our products and services, including the launches of our next-generation probe, P5 chip, Apollo chip, and fourth-generation technology; the potential for our semiconductor platform to enable new markets through Butterfly Embedded partnerships; expectations regarding the growth of our medical education partnerships and their impact on long-term adoption; and the growth of our Butterfly Garden™ partner ecosystem and AI marketplace. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, as applicable, and any related restrictions and limitations on the use of any authorized product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; the success, cost, and timing of our efforts to out-license our intellectual property to third parties; our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us; changes in applicable laws or regulations; the impact of global macroeconomic conditions, including tariffs, geopolitical conflicts, and AI-driven supply chain shortages on our business and operations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to attract and retain customers; our ability to manage our growth effectively; our ability to protect or enforce our intellectual property rights; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.

BUTTERFLY NETWORK, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (Unaudited)
Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
Revenue:
Product $ 15,627 $ 14,556 $ 46,001 $ 45,341
Software and other services 16,971 6,933 45,740 20,755
Total revenue 32,598 21,489 91,741 66,096
Cost of revenue:
Product 6,834 23,552 20,558 36,047
Software and other services 1,962 1,694 5,805 5,536
Total cost of revenue 8,796 25,246 26,363 41,583
Gross profit (loss) 23,802 (3,757 ) 65,378 24,513
Operating expenses:
Research and development 10,171 8,703 30,251 26,942
Sales and marketing 11,604 10,626 34,488 33,805
General and administrative 11,561 9,289 33,734 28,018
Other 4,045 2,759 8,018 5,451
Total operating expenses 37,381 31,377 106,491 94,216
Loss from operations (13,579 ) (35,134 ) (41,113 ) (69,703 )
Interest income 1,069 1,443 3,334 4,598
Interest expense (284 ) (385 ) (845 ) (1,100 )
Change in fair value of warrant liabilities — 207 413 1,652
Other income (expense), net (13 ) (86 ) (183 ) 2,824
Loss before provision for income taxes (12,807 ) (33,955 ) (38,394 ) (61,729 )
Provision for income taxes — 16 — 43
Net loss and comprehensive loss $ (12,807 ) $ (33,971 ) $ (38,394 ) $ (61,772 )
Net loss per common share attributable to Class A and B common stockholders, basic and diluted $ (0.05 ) $ (0.13 ) $ (0.15 ) $ (0.25 )
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted 266,497,535 252,087,541 261,741,489 245,197,834
BUTTERFLY NETWORK, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited)
September 30, 2026 December 31, 2025
Assets
Current assets:
Cash and cash equivalents $ 122,301 $ 150,489
Accounts receivable, net of allowance for credit losses of $2,015 and $1,389 at September 30, 2026 and December 31, 2025, respectively 37,378 26,744
Inventories 59,584 61,389
Current portion of vendor advances 2,922 2,063
Prepaid expenses and other current assets 21,484 8,418
Total current assets 243,669 249,103
Property and equipment, net 15,851 16,587
Intangible assets, net 6,466 7,516
Non-current portion of vendor advances 4,798 5,008
Operating lease assets 11,366 12,652
Other non-current assets 5,825 5,667
Total assets $ 287,975 $ 296,533
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $ 5,657 $ 5,442
Deferred revenue, current 15,926 26,909
Accrued purchase commitments, current — 131
Warrant liabilities, current — 413
Accrued expenses and other current liabilities 46,404 32,222
Total current liabilities 67,987 65,117
Deferred revenue, non-current 11,133 9,391
Operating lease liabilities 15,546 17,721
Other non-current liabilities 8,864 8,325
Total liabilities 103,530 100,554
Commitments and contingencies
Stockholders’ equity:
Class A common stock $0.0001 par value; 600,000,000 shares authorized at September 30, 2026 and December 31, 2025; 245,905,451 and 227,318,426 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively 25 23
Class B common stock $0.0001 par value; 27,000,000 shares authorized at September 30, 2026 and December 31, 2025; 21,426,937 and 26,426,937 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively 2 3
Additional paid-in capital 1,102,006 1,075,147
Accumulated deficit (917,588 ) (879,194 )
Total stockholders’ equity 184,445 195,979
Total liabilities and stockholders’ equity $ 287,975 $ 296,533
BUTTERFLY NETWORK, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
Nine months ended September 30,
2026 2025
Cash flows from operating activities:
Net loss $ (38,394 ) $ (61,772 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization, and impairments 5,086 6,327
Non-cash interest expense 844 1,099
Write-down of inventories — 7,931
Write-down of vendor advances — 9,621
Stock-based compensation expense 19,312 17,074
Change in fair value of warrant liabilities (413 ) (1,652 )
Other 1,375 346
Changes in operating assets and liabilities:
Accounts receivable (11,999 ) (3,972 )
Inventories 1,805 626
Prepaid expenses and other assets (13,209 ) (1,114 )
Vendor advances (649 ) 3,208
Accounts payable 154 (943 )
Deferred revenue (9,241 ) 832
Accrued purchase commitments (131 ) —
Change in operating lease assets and liabilities (698 ) (633 )
Accrued expenses and other liabilities 13,729 1,291
Net cash used in operating activities (32,429 ) (21,731 )
Cash flows from investing activities:
Purchases of property, equipment, and intangible assets, including capitalized software (3,069 ) (2,265 )
Net cash used in investing activities (3,069 ) (2,265 )
Cash flows from financing activities:
Proceeds from exercise of stock options 6,084 274
Proceeds from employee stock purchase plan 1,233 949
Net proceeds from share offering — 81,006
Payments to tax authorities for restricted stock units withheld (7 ) (2,775 )
Net cash provided by financing activities 7,310 79,454
Net increase (decrease) in cash, cash equivalents, and restricted cash (28,188 ) 55,458
Cash, cash equivalents, and restricted cash, beginning of period 154,504 92,790
Cash, cash equivalents, and restricted cash, end of period $ 126,316 $ 148,248
BUTTERFLY NETWORK, INC. ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN (In thousands) (Unaudited)
Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
Revenue $ 32,598 $ 21,489 $ 91,741 $ 66,096
Cost of revenue 8,796 25,246 26,363 41,583
Gross profit (loss) $ 23,802 $ (3,757 ) $ 65,378 $ 24,513
Gross margin 73.0 % (17.5 %) 71.3 % 37.1 %
Add:
Write-downs and write-offs of inventories and vendor advances — 17,486 — 17,552
Adjusted gross profit $ 23,802 $ 13,729 $ 65,378 $ 42,065
Adjusted gross margin 73.0 % 63.9 % 71.3 % 63.6 %
Depreciation and amortization $ 649 $ 864 $ 2,118 $ 3,405
% of revenue 2.0 % 4.0 % 2.3 % 5.2 %
BUTTERFLY NETWORK, INC. ADJUSTED EBITDA AND ADJUSTED EPS (In thousands, except share and per share amounts) (Unaudited)
Included on the condensed consolidated statements of operations and comprehensive loss as: Three months ended September 30, Nine months ended September 30,
2026 2025 2026 2025
Net loss Net loss $ (12,807 ) $ (33,971 ) $ (38,394 ) $ (61,772 )
Stock-based compensation Cost of revenue, R&D, S&M, and G&A 6,732 4,925 19,312 17,074
Write-downs and write-offs of inventories and vendor advances Cost of revenue — 17,486 — 17,552
Change in fair value of warrant liabilities Change in fair value of warrant liabilities — (207 ) (413 ) (1,652 )
Other Other 4,045 2,759 8,018 5,451
Other expense (income), net Other income (expense), net 13 86 183 (2,824 )
Adjusted net loss (2,017 ) (8,922 ) (11,294 ) (26,171 )
Interest income Interest income (1,069 ) (1,443 ) (3,334 ) (4,598 )
Interest expense Interest expense 284 385 845 1,100
Provision for income taxes Provision for income taxes — 16 — 43
Depreciation and amortization Cost of revenue, R&D, S&M, and G&A 1,615 1,885 5,086 6,327
Adjusted EBITDA $ (1,187 ) $ (8,079 ) $ (8,697 ) $ (23,299 )
EPS Net loss per common share $ (0.05 ) $ (0.13 ) $ (0.15 ) $ (0.25 )
Adjusted EPS $ (0.01 ) $ (0.04 ) $ (0.04 ) $ (0.11 )
Weighted average shares used to compute EPS and adjusted EPS Weighted-average shares used to compute net loss per share 266,497,535 252,087,541 261,741,489 245,197,834

Investors
John Doherty
Chief Financial Officer, Butterfly
[email protected]

Media
Liz Snyder
Director, PR & Communications, Butterfly
[email protected]

Source: Butterfly Network, Inc.

View All News

Learn

About

Help

Follow us

  • twitter

  • instragram

  • facebook

  • linkedIn

  • youTube

For prescription use only. Butterfly iQ+/iQ3™ is a portable ultrasound system designed for external ultrasound imaging. Read the User Manual for warnings, precautions and/or contraindications.

Not all presets, imaging modes and features are available everywhere. Check for availability in your country, subscription type, and software version.

Names and data used in examples on product screens are fictitious unless otherwise noted.

All comparative claims are made relative to second-generation iQ+ product.

TeleGuidance™ is only available for compatible iOS devices and is not currently supported on iQ3.

Tutorials on, or linked to, from this page are not a substitute for professional clinician training.

ScanLab is for educational use only and not for diagnostic use. ScanLab is a separately downloadable educational app included with your Butterfly membership.

*Your rate will be 0% APR or 10-36% APR based on credit, and is subject to an eligibility check. For example, a $3,119 purchase might cost $87/mo over 36 months at 0% APR. Payment options through Affirm are provided by these lending partners: Affirm's lending partners . Options depend on your purchase amount, and a down payment may be required.

© 2026 Butterfly Network, Inc.

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

10/27/2026

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)-- Butterfly Network, Inc . (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, cloud software and AI, today announced that it will attend the UBS Global Healthcare Conference in Palm Beach Garden, FL on November 10, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman and John Doherty, EVP, Chief Financial Officer, will present and host one-on-one investor meetings. The company presentation will occur at 8:45 AM - 9:20 AM ET on November 10.

A webcast of the presentation will be available in the Events & Presentations section of the Butterfly investor website (https://ir.butterflynetwork.com/events-and-presentations ).

To schedule a one-on-one meeting with Butterfly management, please reach out to your UBS representative.

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is driving a digital revolution in ultrasound imaging and sensing with its proprietary Ultrasound-on-Chip™ semiconductor technology and software solutions. Butterfly first proved its technology in the point-of-care ultrasound market – commercializing the world's first single-probe, whole-body portable ultrasound device, which is now on its best-selling, third-generation: Butterfly iQ3™. The Company combines its advanced hardware with cloud software and AI, an enterprise workflow solution (Compass AI™) and other offerings to drive adoption of affordable, accessible ultrasound. Butterfly also enables third-party development of imaging AI apps through Butterfly Garden™, its software development kit and AI marketplace.

In addition to its medical imaging products, Butterfly Embedded™ is the Company's Ultrasound-on-Chip™ licensing and co-development business designed to enable a new wave of ultrasound-enabled technologies across non-competitive healthcare markets and beyond. Through Butterfly Embedded™, partners can build and scale novel ultrasound applications powered by Butterfly's proprietary semiconductor chip and software platform.

Butterfly's innovations have been recognized by Prix Galien USA, Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. To learn more, visit: www.butterflynetwork.com .

Investors:
John Doherty
Chief Financial Officer
[email protected]

Source: Butterfly Network, Inc.

View All News

Learn

About

Help

Follow us

  • twitter

  • instragram

  • facebook

  • linkedIn

  • youTube

For prescription use only. Butterfly iQ+/iQ3™ is a portable ultrasound system designed for external ultrasound imaging. Read the User Manual for warnings, precautions and/or contraindications.

Not all presets, imaging modes and features are available everywhere. Check for availability in your country, subscription type, and software version.

Names and data used in examples on product screens are fictitious unless otherwise noted.

All comparative claims are made relative to second-generation iQ+ product.

TeleGuidance™ is only available for compatible iOS devices and is not currently supported on iQ3.

Tutorials on, or linked to, from this page are not a substitute for professional clinician training.

ScanLab is for educational use only and not for diagnostic use. ScanLab is a separately downloadable educational app included with your Butterfly membership.

*Your rate will be 0% APR or 10-36% APR based on credit, and is subject to an eligibility check. For example, a $3,119 purchase might cost $87/mo over 36 months at 0% APR. Payment options through Affirm are provided by these lending partners: Affirm's lending partners . Options depend on your purchase amount, and a down payment may be required.

© 2026 Butterfly Network, Inc.

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

Skip to main content

Contact Support Contact Sales Log In English Language. Choose Your Language

Butterfly Network

Butterfly Network

Products

Whole-body Probes



iQ3 Award winner

Our third-generation probe with double the processing power and clearer images.


iQ+

Our second-generation single-probe,
whole-body imaging device.


Why Butterfly

Butterfly brings the power of ultrasound into your assessment, diagnosis and treatment.

Application-Specific Probes



Butterfly Move NEW

Our first all-in-one POCUS cart


iQ+ Bladder™

The bladder scanner that gives automated calculations in seconds.


iQ3 Vet™ NEW

Next gen, all-species veterinary imaging solution.

Software & Services



Compass AI™ NEW

Integrate your entire ultrasound program on one streamlined software solution.


Education

Tutorials, training packages, and courses created by our experts.


AI Marketplace

Explore AI-powered apps, compatible with your Butterfly probe.


Developers

Build custom apps compatible with Butterfly probes, tailored to your speciality.

Specialties

BY SPECIALTY

Anesthesiology Cardiology Critical Care Emergency Medicine EMS

Hospital Medicine MSK Nursing OB/GYN Primary Care

Urology Veterinary

BY use case

Clinician scanning a patient's chest with a Butterfly probe and smartphone

Health Systems

An integrated ultrasound platform for your entire care system.


Educational Programs

Bring the power of Butterfly to your medical school or residency program.


Student & Residents

Unlock your potential and differentiate your skillset with exclusive pricing for trainees.


Global Health

Maximize your impact in resource-limited settings with Butterfly.

Pricing Resources

About Us

About us

Butterfly Embedded™ Ultrasound-on-Chip™ Mission Sustainability Press

Community

Investors Partners Careers Customer Support Contact Sales

Contactar a Ventas

Ver Demostración

Offers

Get a demo Buy

Offers Buy

Contact sales Get a demo

The Edward Via College of Osteopathic Medicine (VCOM) and Butterfly Network Announce Long-Term Alliance to Build New Model for Ultrasound Education

Joint investment will establish VCOM as a center of excellence for ultrasound education, in a first-of-its-kind model combining 1:1 probe deployment and integrated education with longitudinal tracking from medical school through clinical practice in rural communities.

BURLINGTON, Mass. & BLACKSBURG, Va.--(BUSINESS WIRE )--The Edward Via College of Osteopathic Medicine (VCOM) and Butterfly Network, Inc. (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound devices, cloud software and AI, today announced a long-term alliance and joint investment in establishing VCOM and its students as a center of excellence for ultrasound education and community care. The first-of-its-kind program combines one-probe-per-student deployment, integrated education and longitudinal analysis through Butterfly’s cloud platform to connect ultrasound education with its real-world use and impact on imaging access, with a focus on rural care.

VCOM graduates approximately 660 osteopathic physicians each year, the majority of whom go on to practice in rural and medically underserved communities. Beginning with the 2026 incoming class, VCOM intends to give every first-year student a Butterfly iQ3 device to use throughout their training and beyond. Butterfly is investing alongside VCOM by offering the medical college meaningfully discounted Butterfly iQ+ devices for all of its remaining students, including every graduating fourth-year student to take with them into residency and clinical practice.

Unlike traditional education partnerships that conclude at graduation, the alliance follows physicians into practice through the Lighthouse Program: an initiative combining continuous learning, remote peer collaboration and real-world practice insights. Connected through Butterfly’s cloud software, participating physicians will contribute longitudinal data that can strengthen training, software development and AI innovation, while advancing understanding of POCUS adoption across diverse clinical settings. As each new class progresses from medical school into practice, the program will build an expanding longitudinal dataset to support future improvement and developments.

"Our mission has always been to prepare physicians to care for the communities that need them most," said Tom Lindsey, DO, FACOS, CHSE, Associate Dean of Simulation and Educational Technology, Lead Medical Education Specialist and Professor of Surgery at the Edward Via College of Osteopathic Medicine. "By placing handheld ultrasound in our students’ hands from the beginning of medical school and ensuring they carry it into practice, we’re preparing generations of physicians who will bring POCUS to rural and underserved communities throughout their careers. Every graduating class will go on to care for millions of patients over the course of their careers. By creating a flywheel model where their experience helps inform the next, we’re multiplying the impact of every student we train."

"Healthcare is moving closer to the patient, and ultrasound is becoming an essential part of the physical exam," said Joseph DeVivo, President, Chief Executive Officer and Chairman of Butterfly Network. "Most education partnerships end at graduation. Ours is designed to grow with clinicians throughout their careers because that’s what’s missing today. Healthcare needs a better way to learn from how technology is used in real clinical practice – and turn those insights into better education, better technology and ultimately better patient care. By combining VCOM’s leadership in education and broad community reach with Butterfly’s imaging platform and unique cloud advantage, we’re filling that gap at a scale the industry has never seen before."

Additional information about the collaboration was published by VCOM at: https://www.vcom.edu/news/2026/10/12/vcom-equips-every-student-handheld-ultrasound-technology .

About Edward Via College of Osteopathic Medicine

The Edward Via College of Osteopathic Medicine (VCOM) is a private, nonprofit medical school based in Blacksburg, Virginia, with branch campuses in Spartanburg, South Carolina; Auburn Alabama; and Monroe, Louisiana. The college provides osteopathic medical education and conducts research aimed at preparing physicians to serve rural and medically underserved Communities. VCOM’s mission is to address physician shortages in the Appalachian and Delta regions by training patient-centered physicians who practice evidence-based medicine. The college places particular emphasis on recruiting students from rural and underserved areas who intend to return to similar communities to practice. To date, more than 82% of VCOM graduates have returned to the region, and over 60% are practicing in rural or medically underserved counties, including federally designated primary care shortage areas.

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.

Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country .

Prompts

Butterfly Network, Inc. (ticker BFLY), listed in United States.

Company History

Date Change Detail
Dec 24, 2020 Renamed LONGVIEW ACQUISITION CORP. → BUTTERFLY NETWORK, INC.

ETFs Holding Butterfly Network, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 1.68% 5,308,710 $ 30.525M Nov 18, 2026
FSEG 0.32% 2,168 $ 18.255K Jun 30, 2026
FESM 0.23% 1,562,912 $ 13.16M Jun 30, 2026
VFMO 0.16% 389,918 $ 3.076M Aug 31, 2026
MSSM 0.01% 13,520 $ 106.673K Aug 31, 2026
DFAS 0.01% 643,259 $ 4.291M Nov 12, 2026
DFAC 0.00% 304,911 $ 2.034M Nov 12, 2026
DFAU 0.00% 39,573 $ 263.952K Nov 12, 2026
DFUS 0.00% 36,517 $ 243.568K Nov 12, 2026
DCOR 0.00% 57,385 $ 382.758K Nov 12, 2026
DXUV 0.00% 836 $ 5,576.12 Nov 12, 2026
DFSU 0.00% 200 $ 1,334.00 Nov 12, 2026